accountdriver, rose 20 percent to $349 million, from $292 million. Analysts were expecting about $337 million. Sales of multiple sclerosis drug Avonex rose 8 percent to $642 million. (Reporting by Toni Clarke; Editing by Lisa Von Ahn...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to UPDATE 1-Biogen first-quarter profit up on MS drug sales
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account